Evolving treatment options for melanoma brain metastases

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages e486-e497

  Ajithkumar, Thankamma ^a   Parkinson, Christine ^a   Fife, Kate ^a   Corrie, Pippa ^a   Jefferies, Sarah ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COBIMETINIB; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GADOLINIUM; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HUMAN; IN VITRO STUDY; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; VISCERAL METASTASIS; WHOLE BRAIN RADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BRAIN NEOPLASMS; MELANOMA; MOLECULARLY TARGETED THERAPY; MORTALITY; NEUROSURGERY; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SECONDARY; SKIN NEOPLASMS; SKULL IRRADIATION; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CRANIAL IRRADIATION; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEUROSURGICAL PROCEDURES; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84953869069     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00141-2     Document Type: Review

References (80)

1. Sampson JH, Carter JH, Friedman AH, Seigler HF Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88:11-20.
2. Nieder C, Adam M, Astner ST Disease presentation and outcome in young patients (<40 years) with brain metastases from malignant melanoma. Anticancer Res 2008, 28:1325-1327.
3. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004, 22:1293-1300.
4. Fonkem E, Uhlmann EJ, Floyd SR, et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 2012, 12:1207-1215.
5. Corrie P, Hategan M, Fife K, Parkinson C Management of melanoma. Br Med Bull 2014, 111:149-162.
6. Gumusay O, Coskun U, Akman T, et al. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian Society of Medical Oncology. J Cancer Res Clin Oncol 2014, 140:151-157.
7. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660-668.
8. Bedikian AY, Wei C, Detry M, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 2011, 34:603-610.
9. Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
10. Carlino MS, Haydu LE, Kakavand H, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 2014, 111:292-299.
11. Ewend MG, Carey LA, Brem H Treatment of melanoma metastases in the brain. Semin Surg Oncol 1996, 12:429-435.
12. Escott EJ A variety of appearances of malignant melanoma in the head: a review. Radiographics 2001, 21:625-639.
13. Kang TW, Kim ST, Byun HS, et al. Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis. Eur J Radiol 2009, 72:370-380.
14. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015, 16:e270-e278.
15. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011, 98:394-399.
16. Morris SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 2004, 91:829-833.
17. la Fuente M, Beal K, Carvajal R, Kaley TJ Whole-brain radiotherapy in patients with brain metastases from melanoma. CNS Oncol 2014, 3:401-406.
18. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980, 6:1-9.
19. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012, 4. CD003869.
20. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
21. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 2014, 32:3810-3816.
22. Fogarty G, Morton RL, Vardy J, et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients-a randomised phase III trial. BMC Cancer 2011, 11:142.
23. Hong AM, Suo C, Valenzuela M, et al. Low incidence of melanoma brain metastasis in the hippocampus. Radiother Oncol 2014, 111:59-62.
24. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 2010, 95:327-331.
25. Hauswald H, Habl G, Krug D, et al. Whole brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial. Radiat Oncol 2013, 8:234.
26. Chang WS, Kim HY, Chang JW, Park YG, Chang JH Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?. J Neurosurg 2010, 113(suppl):73-78.
27. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
28. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33:583-590.
29. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29:711-717.
30. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470-1476.
31. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
32. Kellogg RG, Straus DC, Choi M, Chaudhry TA, Diaz AZ, Munoz LF Stereotactic radiosurgery boost to the resection cavity for cerebral metastases: report of overall survival, complications, and corticosteroid protocol. Surg Neurol Int 2013, 4(suppl 6):S436-S442.
33. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134-141.
34. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
35. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45:427-434.
36. Auchter RM, Lamond JP, Alexander E, et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996, 35:27-35.
37. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012, 30:419-425.
38. Fogarty GB, Hong A, Dolven-Jacobsen K, et al. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Res Notes 2015, 8:192.
39. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125.
40. Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003, 13:97-103.
41. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002, 25:82-87.
42. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
43. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015, 33:1191-1196.
44. Puzanov I, Wolchok JD, Ascierto PA, Hamid O, Margolin K Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. Expert Rev Dermatol 2013, 8:479-487.
45. Lebbé CMD, Robert C, Ottensmeier CH, et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial. Ann Oncol 2010, 21(suppl 8):viii401-vii2007.
46. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465.
47. Heller KN, Pavlick AC, Hodi FS, et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Proc Am Soc Clin Oncol 2011, 29(suppl).
48. Di Giacomo AM, Ascierto PA, Queirolo P, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015, 26:798-803.
49. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012, 13:879-886.
50. Queirolo P, Spagnolo F, Ascierto PA, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014, 118:109-116.
51. Ahmad S, Qian W, Ellis S, et al. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res 2015, 25:432-442.
52. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015, 33:1889-1894.
53. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
54. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372:2521-2532.
55. Rochet NM, Kottschade LA, Markovic SN Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011, 365:2439-2441.
56. V600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014, 50:611-621.
57. Dzienis MR, Atkinson VG Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res 2014, 24:349-353.
58. Harding JJ, Catalanotti F, Munhoz RR, et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist 2015, 20:789-797.
59. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
60. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
61. Azer MW, Menzies AM, Haydu LE, Kefford RF, Long GV Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 2014, 120:530-536.
62. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
63. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015, 372:30-39.
64. Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol; 31: e40-43.
65. Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos 2014, 42:1292-1300.
66. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
67. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012, 117:227-233.
68. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013, 2:899-906.
69. Tazi K, Hathaway A, Chiuzan C, Shirai K Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 2015, 4:1-6.
70. Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013, 23:191-195.
71. Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 2015, published online May 16. 10.1097/COC.0000000000000199.
72. Du Four S, Hong A, Chan M, et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med 2014, 2014:417913.
73. Khoja L, Kurtz G, Bernstein M, et al. Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: does an enhanced immune response induce radionecrosis (RN)?. Proc Am Soc Clin Oncol 2015, 33(suppl). abstr e20019.
74. Hanna GG, Coyle VM, Prise KM Immune modulation in advanced radiotherapies: Targeting out-of-field effects. Cancer Lett 2015, published online April 16. 10.1016/j.canlet.2015.04.007.
75. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
76. Narayana A, Mathew M, Tam M, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013, 113:411-416.
77. Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013, 149:855-857.
78. Kyritsis AP, Markoula S, Levin VA A systematic approach to the management of patients with brain metastases of known or unknown primary site. Cancer Chemother Pharmacol 2012, 69:1-13.
79. Wang J, Guo ZZ, Wang YJ, Zhang SG, Xing DG Microsurgery for the treatment of primary malignant intracranial melanoma: a surgical series and literature review. Eur J Surg Oncol 2014, 40:1062-1071.
80. Greco Crasto S, Soffietti R, Bradac GB, Boldorini R Primitive cerebral melanoma: case report and review of the literature. Surg Neurol 2001, 55:163-168.